Genital Herpes - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 107 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Genital Herpes - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Genital Herpes - Pipeline Review, H2 2016', provides an overview of the Genital Herpes pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Genital Herpes, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Genital Herpes and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Genital Herpes
- The report reviews pipeline therapeutics for Genital Herpes by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Genital Herpes therapeutics and enlists all their major and minor projects
- The report assesses Genital Herpes therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Genital Herpes

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Genital Herpes
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Genital Herpes pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Genital Herpes Overview 10
Therapeutics Development 11
Pipeline Products for Genital Herpes - Overview 11
Pipeline Products for Genital Herpes - Comparative Analysis 12
Genital Herpes - Therapeutics under Development by Companies 13
Genital Herpes - Therapeutics under Investigation by Universities/Institutes 15
Genital Herpes - Pipeline Products Glance 16
Clinical Stage Products 16
Early Stage Products 17
Genital Herpes - Products under Development by Companies 18
Genital Herpes - Products under Investigation by Universities/Institutes 19
Genital Herpes - Companies Involved in Therapeutics Development 20
Admedus Ltd 20
Agenus, Inc. 21
AiCuris GmbH & Co. KG 22
Foamix Pharmaceuticals Ltd. 23
Genocea Biosciences, Inc. 24
GenVec, Inc. 25
Immune Design Corp. 26
JN-International Medical Corporation 27
Mymetics Corporation 28
NanoBio Corporation 29
NanoViricides, Inc. 30
PaxVax, Inc. 31
Profectus BioSciences, Inc. 32
Redbiotec AG 33
Sanofi Pasteur SA 34
Shulov Innovative Science Ltd. 35
Starpharma Holdings Limited 36
Tomegavax, Inc. 37
Vaccibody AS 38
Vaxart, Inc. 39
Vical Incorporated 40
Genital Herpes - Therapeutics Assessment 41
Assessment by Monotherapy Products 41
Assessment by Target 42
Assessment by Mechanism of Action 44
Assessment by Route of Administration 46
Assessment by Molecule Type 48
Drug Profiles 50
acyclovir - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
Aspidasept - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
astodrimer - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
G-103 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
GEN-002 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
GEN-003 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
genital herpes (virus like particle) vaccine - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
genital herpes vaccine - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
genital herpes vaccine - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
genital herpes vaccine - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
genital herpes vaccine - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
genital herpes vaccine - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
GV-2207 - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
herpes simplex virus [type 1, 2] vaccine - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
herpes simplex virus [type 1, 2] vaccine - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
herpes simplex virus 2 vaccine - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
herpes simplex virus 2 vaccine - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
herpes simplex virus 2 vaccine - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
herpes simplex virus 2 vaccine - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
herpes simplex virus 2 vaccine - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
herpes simplex virus 2 vaccine - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
HSV-529 - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
pritelivir - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
Small Molecule for Genital Herpes - Drug Profile 83
Product Description 83
Mechanism Of Action 83
R&D Progress 83
VCLHB-01 - Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
VCLHM-01 - Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
ZEP-3 - Drug Profile 88
Product Description 88
Mechanism Of Action 88
R&D Progress 88
Genital Herpes - Dormant Projects 90
Genital Herpes - Discontinued Products 92
Genital Herpes - Product Development Milestones 93
Featured News & Press Releases 93
Jun 20, 2016: A novel therapy for genital herpes engages immune cells to provide significant patient benefits 93
Jun 09, 2016: Genocea Showcases Potential of Genital Herpes Immunotherapy GEN-003 at ASM Microbe 2016 93
Mar 31, 2016: Genital Herpes Immunotherapy GEN-003 Shows Sustained Reduction of Viral Shedding Rate, Durable Impact on Clinical Disease 12 Months Post-Dosing 94
Mar 04, 2016: Interim HSV-2 Phase II clinical trial data encouraging 95
Feb 03, 2016: Model helps decide drug dose for clinical testing 96
Jan 29, 2016: Genocea Commences Dosing in Phase 2b Study for Genital Herpes Treatment, GEN-003 96
Oct 07, 2015: Genocea Announces Positive Durability Data from 6-Month Analysis of Phase 2 Clinical Trial of Genital Herpes Immunotherapy GEN-003 97
Sep 22, 2015: NanoBio's Genital Herpes Vaccine Demonstrates Efficacy In Guinea Pigs As Both A Prophylactic And A Therapeutic Vaccine 98
Aug 17, 2015: Vaxart to Present at the 6th Euro Global Summit and Expo on Vaccines and Vaccination in Birmingham, UK on August 18, 2015 99
May 20, 2015: Genocea Announces Positive Top-Line Phase 2 Data for Genital Herpes Immunotherapy GEN-003 99
Apr 10, 2015: Admedus has high hopes for Herpes vaccine as dosing commences 100
Jan 07, 2015: Genocea Completes Enrollment Early in Phase 2 Dose Optimization Trial of GEN-003 for Treatment of Genital Herpes 101
Oct 08, 2014: NanoBio To Present Data Demonstrating The Potential For Its Intranasal Vaccine To Protect Against Genital Herpes Infection 102
Jun 26, 2014: Agenus Vaccine Shows Significant Reduction in Viral Burden After HerpV Generated Immune Activation 103
Nov 07, 2013: Agenus' HerpV Therapeutic Vaccine for Genital Herpes Meets Primary Endpoint in Randomized Phase 2 Trial 104
Appendix 106
Methodology 106
Coverage 106
Secondary Research 106
Primary Research 106
Expert Panel Validation 106
Contact Us 106
Disclaimer 107

List of Tables

Number of Products under Development for Genital Herpes, H2 2016 11
Number of Products under Development for Genital Herpes - Comparative Analysis, H2 2016 12
Number of Products under Development by Companies, H2 2016 14
Number of Products under Investigation by Universities/Institutes, H2 2016 15
Comparative Analysis by Clinical Stage Development, H2 2016 16
Comparative Analysis by Early Stage Development, H2 2016 17
Products under Development by Companies, H2 2016 18
Products under Investigation by Universities/Institutes, H2 2016 19
Genital Herpes - Pipeline by Admedus Ltd, H2 2016 20
Genital Herpes - Pipeline by Agenus, Inc., H2 2016 21
Genital Herpes - Pipeline by AiCuris GmbH & Co. KG, H2 2016 22
Genital Herpes - Pipeline by Foamix Pharmaceuticals Ltd., H2 2016 23
Genital Herpes - Pipeline by Genocea Biosciences, Inc., H2 2016 24
Genital Herpes - Pipeline by GenVec, Inc., H2 2016 25
Genital Herpes - Pipeline by Immune Design Corp., H2 2016 26
Genital Herpes - Pipeline by JN-International Medical Corporation, H2 2016 27
Genital Herpes - Pipeline by Mymetics Corporation, H2 2016 28
Genital Herpes - Pipeline by NanoBio Corporation, H2 2016 29
Genital Herpes - Pipeline by NanoViricides, Inc., H2 2016 30
Genital Herpes - Pipeline by PaxVax, Inc., H2 2016 31
Genital Herpes - Pipeline by Profectus BioSciences, Inc., H2 2016 32
Genital Herpes - Pipeline by Redbiotec AG, H2 2016 33
Genital Herpes - Pipeline by Sanofi Pasteur SA, H2 2016 34
Genital Herpes - Pipeline by Shulov Innovative Science Ltd., H2 2016 35
Genital Herpes - Pipeline by Starpharma Holdings Limited, H2 2016 36
Genital Herpes - Pipeline by Tomegavax, Inc., H2 2016 37
Genital Herpes - Pipeline by Vaccibody AS, H2 2016 38
Genital Herpes - Pipeline by Vaxart, Inc., H2 2016 39
Genital Herpes - Pipeline by Vical Incorporated, H2 2016 40
Assessment by Monotherapy Products, H2 2016 41
Number of Products by Stage and Target, H2 2016 43
Number of Products by Stage and Mechanism of Action, H2 2016 45
Number of Products by Stage and Route of Administration, H2 2016 47
Number of Products by Stage and Molecule Type, H2 2016 49
Genital Herpes - Dormant Projects, H2 2016 90
Genital Herpes - Dormant Projects (Contd..1), H2 2016 91
Genital Herpes - Discontinued Products, H2 2016 92